



## Notice of Results

July 15, 2022

RNS Number : 6595S

MaxCyte, Inc.

15 July 2022

## MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

GAITHERSBURG, MD, July 15, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the second quarter of 2022 after the U.S. market close on Wednesday, August 10<sup>th</sup>, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

### Conference Call Details

Investors interested in listening to the conference call are required to [register online](#). It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at <https://investors.maxcyte.com/>.

### About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation<sup>®</sup> platform, which facilitates complex engineering of a wide variety of cells. Our EXPERT<sup>™</sup> platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The EXPERT family of products includes: four instruments, the ATx<sup>™</sup>, STx<sup>™</sup>, GTx<sup>™</sup> and VLx<sup>™</sup>; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

### MaxCyte Contacts:

#### *US IR Adviser*

#### **Gilmartin Group**

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

#### *Nominated Adviser and Joint Corporate Broker*

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

#### *UK IR Adviser*

#### **Consilium Strategic Communications**

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUVSKRUNUBARR